Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.67 Insider Own8.99% Shs Outstand66.69M Perf Week-3.25%
Market Cap84.30M Forward P/E- EPS next Y-1.06 Insider Trans0.29% Shs Float64.47M Perf Month-5.56%
Income-114.62M PEG- EPS next Q-0.34 Inst Own89.38% Short Float9.82% Perf Quarter33.69%
Sales21.43M P/S3.93 EPS this Y-21.22% Inst Trans0.40% Short Ratio2.55 Perf Half Y-83.63%
Book/sh2.21 P/B0.54 EPS next Y34.25% ROA-47.17% Short Interest6.33M Perf Year-90.62%
Cash/sh1.45 P/C0.82 EPS next 5Y- ROE-60.94% 52W Range0.59 - 13.09 Perf YTD13.33%
Dividend Est.- P/FCF- EPS past 5Y11.39% ROI-72.47% 52W High-90.91% Beta0.23
Dividend TTM- Quick Ratio4.50 Sales past 5Y91.61% Gross Margin80.35% 52W Low101.63% ATR (14)0.09
Dividend Ex-Date- Current Ratio4.50 EPS Y/Y TTM-29.39% Oper. Margin-498.95% RSI (14)48.93 Volatility6.97% 6.87%
Employees105 Debt/Eq0.01 Sales Y/Y TTM-8.80% Profit Margin-534.83% Recom2.78 Target Price3.00
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q-38.10% Payout- Rel Volume0.29 Prev Close1.21
Sales Surprise489.82% EPS Surprise14.55% Sales Q/Q-51.19% EarningsNov 06 BMO Avg Volume2.48M Price1.19
SMA20-0.42% SMA505.53% SMA200-78.71% Trades Volume718,773 Change-1.65%
Date Action Analyst Rating Change Price Target Change
Jan-22-24Downgrade H.C. Wainwright Buy → Neutral
Nov-13-23Downgrade William Blair Outperform → Mkt Perform
Oct-03-23Initiated Evercore ISI Outperform $22
Dec-14-22Initiated Stifel Buy $29
Dec-01-22Initiated Goldman Buy $25
Oct-06-22Initiated BTIG Research Buy $32
Jul-23-21Resumed Jefferies Buy $27 → $32
Jun-15-21Initiated Piper Sandler Overweight $30
Apr-21-21Initiated H.C. Wainwright Buy $40
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Feb-15-24 10:00AM
Feb-13-24 09:40AM
Jan-17-24 11:14AM
Jan-16-24 07:00AM
Jan-10-24 07:00AM
09:40AM Loading…
Jan-04-24 09:40AM
Dec-19-23 04:01PM
Dec-05-23 04:01PM
Dec-04-23 09:35AM
Nov-16-23 09:35AM
Nov-14-23 10:57AM
Nov-13-23 07:17AM
Nov-06-23 08:03AM
07:06AM Loading…
Oct-03-23 07:00AM
Sep-20-23 07:00AM
Sep-18-23 07:00AM
Sep-14-23 07:03PM
Sep-08-23 05:06PM
Aug-10-23 06:07AM
Aug-08-23 08:40AM
Aug-07-23 08:15AM
Aug-01-23 07:53AM
Jul-06-23 08:19AM
Jun-26-23 10:15AM
06:30PM Loading…
Jun-13-23 06:30PM
Jun-02-23 07:00AM
May-18-23 01:50PM
May-10-23 06:04AM
May-08-23 11:55PM
May-05-23 06:49AM
May-02-23 07:01AM
Apr-27-23 04:35AM
Apr-24-23 02:37PM
Apr-04-23 07:40AM
Mar-27-23 07:00AM
Mar-10-23 11:34AM
Mar-06-23 03:59PM
Feb-23-23 08:35AM
Feb-22-23 06:01AM
Feb-09-23 04:01PM
Jan-06-23 07:01AM
Nov-29-22 07:00AM
Nov-26-22 01:39PM
Nov-22-22 04:01PM
Nov-16-22 12:10PM
Nov-10-22 04:01PM
Nov-08-22 08:25AM
Oct-26-22 06:44AM
Sep-27-22 07:00AM
Sep-15-22 06:46AM
Aug-30-22 07:00AM
Aug-25-22 07:00AM
Aug-05-22 07:59AM
Aug-03-22 08:25AM
Aug-01-22 07:00AM
Jul-15-22 12:00PM
Jul-08-22 09:40AM
Jul-01-22 09:36AM
Jun-27-22 07:00AM
Jun-22-22 09:40AM
Jun-20-22 08:20AM
Jun-13-22 09:55AM
Jun-06-22 09:40AM
Jun-01-22 04:01PM
May-27-22 09:55AM
May-17-22 11:53AM
May-16-22 07:00AM
May-10-22 08:15AM
May-04-22 07:35PM
May-03-22 07:00AM
May-02-22 06:10AM
Apr-13-22 12:17AM
Feb-24-22 08:55AM
Feb-21-22 04:34AM
Feb-17-22 03:03PM
Feb-06-22 04:33PM
Feb-02-22 07:00AM
Feb-01-22 04:01PM
Jan-11-22 04:01PM
Dec-27-21 07:00AM
Dec-20-21 05:21PM
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Monahan JosephChief Scientific OfficerOct 23Sale5.086,00030,460129,724Oct 25 04:28 PM
Balthaser KevinChief Financial OfficerSep 06Buy7.909,49074,97115,461Sep 07 04:16 PM
Loerop JamesChief Business OfficerAug 28Buy6.8014,70599,95921,688Aug 28 04:39 PM
Monahan JosephChief Scientific OfficerAug 21Sale7.326,00043,895135,724Aug 22 04:31 PM
Molineaux Christopher P.DirectorJun 20Option Exercise1.4116,50023,26548,503Jun 22 04:32 PM
Monahan JosephChief Scientific OfficerJun 20Sale10.286,00061,663141,724Jun 22 04:30 PM
Molineaux Christopher P.DirectorJun 15Option Exercise1.3624933832,003Jun 20 04:31 PM
Manion Douglas J.Pres and CEOMar 17Buy7.866,30049,53212,800Mar 17 05:03 PM
Manion Douglas J.Pres and CEOMar 09Buy7.746,50050,2786,500Mar 09 05:56 PM
Walker NealDirectorMar 03Sale12.6330,240382,0701,273,202Mar 03 08:37 PM
Monahan JosephChief Scientific OfficerMar 03Sale12.6316,037202,615147,724Mar 03 08:12 PM
Balthaser KevinChief Financial OfficerMar 03Sale12.6389411,2905,256Mar 03 08:09 PM
Walker NealDirectorMar 02Sale12.3729,000358,5881,285,188Mar 03 08:37 PM
Monahan JosephChief Scientific OfficerMar 02Sale12.3714,800183,024151,261Mar 03 08:12 PM
Balthaser KevinChief Financial OfficerMar 02Sale12.291,00012,2894,650Mar 03 08:09 PM